Mismanaged measures

April 2008
Nature;4/3/2008, Vol. 452 Issue 7187, p504
Academic Journal
The article discusses the effectiveness of using surrogate devices in monitoring diseases. Surrogate markers are the indirect measures of treating diseases in the clinical trial. This practice will allow the researchers to conduct easy and rapid measurements. However, clinical trials found out that the drug ezetimibe cannot slow the steady march of atherosclerosis in patients having high cholesterol and the combination of insulin and strict diet can increase the mortality rates of people with lower blood-sugar levels. Physicians found out that surrogate markers are not an accurate indicator in determining the important results.


Related Articles

  • Global clinical trial laboratories decentralize. Rosenberg, Ronald // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p1 

    The article reports that central laboratories which have played an important role in drug development, are now looking for decentralization and regional labs are becoming more active in global clinical trials. With sponsors seeking real-time data access and faster results, labs are conducting...

  • Youngevity(r) Essential Life Sciences Initiates Clinical Studies at Clemson University's Institute of Nutraceutical Research.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article informs that the company Youngevity Essential Life Sciences has signed an agreement with the Institute of Nutraceutical Research at Clemson University, Clemson, South Carolina to initiate a series of clinical research studies. The validation research studies will not be tested in...

  • The Association Between Inflammatory Markers and the Extent of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Saremi, Aramesh; Anderson, Robert; Luo, Ping; Moritz, Tom; Schwenke, Dawn; Allison, Matthew; Reaven, Peter D. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA32 

    Evidence implicating inflammatory markers in the development of atherosclerosis and cardiovascular events in nondiabetic populations is increasing. However, data are particularly scarce in individuals with type 2 diabetes (T2DM) and few studies compare multiple inflammatory markers in this...

  • Study Design in Dementia Drug Trials. MacKnight, Chris // Canadian Journal of Neurological Sciences;Mar2007 Supplement 1, Vol. 34, pS19 

    The article focuses on issues surrounding study design in drug trials for dementia in Canada. It is unlikely that a novel study design such as randomized start or withdrawal could provide convincing evidence of disease modification in the absence of an accepted biological marker of progression....

  • Proteomic Profiles in Acute Respiratory Distress Syndrome Differentiates Survivors from Non-Survivors. Bhargava, Maneesh; Becker, Trisha L.; Viken, Kevin J.; Jagtap, Pratik D.; Dey, Sanjoy; Steinbach, Michael S.; Wu, Baolin; Kumar, Vipin; Bitterman, Peter B.; Ingbar, David H.; Wendt, Christine H. // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Acute Respiratory Distress Syndrome (ARDS) continues to have a high mortality. Currently, there are no biomarkers that provide reliable prognostic information to guide clinical management or stratify risk among clinical trial participants. The objective of this study was to probe the...

  • Incorporating biomarkers into clinical trials in cardiovascular medicine. Hsiu-Fang Lee; Sho Ota // Degenerative Neurological & Neuromuscular Disease;2014, Vol. 4, p121 

    Developing novel therapies and establishing clinical benefits over conventional therapies has become a highly competitive and a costly endeavor. In this regard, biomarkers have become increasingly important in accurately assessing both efficacy and safety of these novel therapies. While the use...

  • Imaging as Biomarkers. Adineh, Mehdi // Applied Clinical Trials;Jan2010 Supplement, p16 

    The article discusses the significance of medical imaging techniques as biomarkers in creating an efficient and affordable clinical trials in the U.S. It indicates that medical imaging is use in all phases of new drug development to guide the diagnosis, treatment, and management of disease....

  • Biomarkers: Trends and Potential. Reilly, Patricia L. // Bio-IT World;Mar2005, Vol. 4 Issue 3, p16 

    Predicts the potential and trends for biomarker research and applications. Estimated cost of successful drug development; Investments in technologies and research for specific and sensitive indicators; Need for investment in data integration and data-mining tools; Potential of clinical trial...

  • A Booming Market for Biomarkers. Gonzalez, Jennifer // Pharmaceutical Discovery;Feb2005, Vol. 5 Issue 2, p19 

    The article reports that according to a market analysis report from Frost and Sullivan, titled. Strategic Analysis of Biomarkers in Clinical Trials, the global biomarkers market is expected to grow from S630 million in 2004 to $2.9 billion in 2008--a 28.5% compound annual growth rate....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics